HARMONY BIOSCIENCES HOLDINGS (HRMY)
US4131971040 - Common Stock
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming...
First Week of July 2025 Options Trading For Harmony Biosciences Holdings (HRMY)
HRMY Makes Notable Cross Below Critical Moving Average
Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the "Company") today announced the pricing of the previously announced underwritten public...
Axonis Therapeutics Announces $115 Million Series A Financing
/PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of...
Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the "Company") today announced the commencement of an underwritten public offering of up to...
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript
HRMY earnings call for the period ending September 30, 2024.
Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat
The company is focused on developing its pipeline of sleep and epilepsy drugs.
HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS
WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years On Track to Submit...
HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON OCTOBER 29, 2024
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2024 financial results on Tuesday, October...
HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), will be providing a comprehensive pipeline update at its Investor Day event today,...
HARMONY BIOSCIENCES TO HOST FIRST INVESTOR DAY ON OCTOBER 1, 2024
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), will provide an overview of its robust, late-stage pipeline at an in-person Investor Day at...
First Week of November 15th Options Trading For Harmony Biosciences Holdings (HRMY)
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming...
Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript
HRMY earnings call for the period ending June 30, 2024.
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program...
HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 6, 2024
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2024 financial results on Tuesday, August...
7 Cheap Biotech Stocks With Major Upside Potential
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that the U.S. Food and Drug Administration denied the Citizen Petition filed...
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY
/PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug...
HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1
/PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excessive daytime...
HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the...
Commit To Purchase Harmony Biosciences Holdings At $17.50, Earn 13.4% Annualized Using Options
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
HRMY earnings call for the period ending March 31, 2024.
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.